114 related articles for article (PubMed ID: 21316228)
21. 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
Hoshina Y; Ikegami S; Okuyama A; Fukui H; Inoguchi K; Maruyama T; Fujimoto K; Matsumura Y; Aoyama A; Harada T; Tanaka H; Nakamura T
Bioorg Med Chem Lett; 2005 Jan; 15(1):217-20. PubMed ID: 15582442
[TBL] [Abstract][Full Text] [Related]
22. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.
Singh J; Adams S; Carter MB; Cuervo H; Lee WC; Lobb RR; Pepinsky RB; Petter R; Scott D
Curr Top Med Chem; 2004; 4(14):1497-507. PubMed ID: 15544540
[TBL] [Abstract][Full Text] [Related]
23. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
25. Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
Saku O; Ohta K; Arai E; Nomoto Y; Miura H; Nakamura H; Fuse E; Nakasato Y
Bioorg Med Chem Lett; 2008 Feb; 18(3):1053-7. PubMed ID: 18160288
[TBL] [Abstract][Full Text] [Related]
26. Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
Kopka IE; Young DN; Lin LS; Mumford RA; Magriotis PA; MacCoss M; Mills SG; Van Riper G; McCauley E; Egger LE; Kidambi U; Schmidt JA; Lyons K; Stearns R; Vincent S; Colletti A; Wang Z; Tong S; Wang J; Zheng S; Owens K; Levorse D; Hagmann WK
Bioorg Med Chem Lett; 2002 Feb; 12(4):637-40. PubMed ID: 11844689
[TBL] [Abstract][Full Text] [Related]
27. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma.
Ravensberg AJ; Luijk B; Westers P; Hiemstra PS; Sterk PJ; Lammers JW; Rabe KF
Allergy; 2006 Sep; 61(9):1097-103. PubMed ID: 16918513
[TBL] [Abstract][Full Text] [Related]
28. A small molecule, orally active, alpha4beta1/alpha4beta7 dual antagonist reduces leukocyte infiltration and airway hyper-responsiveness in an experimental model of allergic asthma in Brown Norway rats.
Cortijo J; Sanz MJ; Iranzo A; Montesinos JL; Nabah YN; Alfón J; Gómez LA; Merlos M; Morcillo EJ
Br J Pharmacol; 2006 Mar; 147(6):661-70. PubMed ID: 16432509
[TBL] [Abstract][Full Text] [Related]
29. The discovery of potent, orally bioavailable pyrimidine-5-carbonitrile-6-alkyl CXCR2 receptor antagonists.
Porter DW; Bradley M; Brown Z; Charlton SJ; Cox B; Hunt P; Janus D; Lewis S; Oakley P; O'Connor D; Reilly J; Smith N; Press NJ
Bioorg Med Chem Lett; 2014 Aug; 24(15):3285-90. PubMed ID: 24974342
[TBL] [Abstract][Full Text] [Related]
30. Amidines as amide bond replacements in VLA-4 antagonists.
Kamenecka TM; Park YJ; Lin LS; de Laszlo S; McCauley ED; Van Riper G; Egger L; Kidambi U; Mumford RA; Tong S; Tang W; Colletti A; Teffera Y; Stearns R; MacCoss M; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2004 May; 14(9):2323-6. PubMed ID: 15081033
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics, safety, and tolerability of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers.
Hijazi Y; Welker H; Dorr AE; Tang JP; Blain R; Renzetti LM; Abbas R
J Clin Pharmacol; 2004 Dec; 44(12):1368-78. PubMed ID: 15545307
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.
Goldstein DM; Soth M; Gabriel T; Dewdney N; Kuglstatter A; Arzeno H; Chen J; Bingenheimer W; Dalrymple SA; Dunn J; Farrell R; Frauchiger S; La Fargue J; Ghate M; Graves B; Hill RJ; Li F; Litman R; Loe B; McIntosh J; McWeeney D; Papp E; Park J; Reese HF; Roberts RT; Rotstein D; San Pablo B; Sarma K; Stahl M; Sung ML; Suttman RT; Sjogren EB; Tan Y; Trejo A; Welch M; Weller P; Wong BR; Zecic H
J Med Chem; 2011 Apr; 54(7):2255-65. PubMed ID: 21375264
[TBL] [Abstract][Full Text] [Related]
33. Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
Lin LS; Lanza T; Jewell JP; Liu P; Jones C; Kieczykowski GR; Treonze K; Si Q; Manior S; Koo G; Tong X; Wang J; Schuelke A; Pivnichny J; Wang R; Raab C; Vincent S; Davies P; Maccoss M; Mumford RA; Hagmann WK
J Med Chem; 2009 Jun; 52(11):3449-52. PubMed ID: 19441819
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Liverton NJ; Bednar RA; Bednar B; Butcher JW; Claiborne CF; Claremon DA; Cunningham M; DiLella AG; Gaul SL; Libby BE; Lyle EA; Lynch JJ; McCauley JA; Mosser SD; Nguyen KT; Stump GL; Sun H; Wang H; Yergey J; Koblan KS
J Med Chem; 2007 Feb; 50(4):807-19. PubMed ID: 17249648
[TBL] [Abstract][Full Text] [Related]
35. Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Dyatkin AB; Hoekstra WJ; Kinney WA; Kontoyianni M; Santulli RJ; Kimball ES; Fisher MC; Prouty SM; Abraham WM; de Garavilla L; Andrade-Gordon P; Hlasta DJ; He W; Hornby PJ; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2004 Feb; 14(3):591-6. PubMed ID: 14741249
[TBL] [Abstract][Full Text] [Related]
36. Orally available and efficacious α4β1/α4β7 integrin inhibitors.
Xu YZ; Smith JL; Semko CM; Rossiter KI; Fukuda JY; Dappen MS; Quincy DA; Konradi AW; Mao W; Welch B; Dreyer ML; Samant B; Zhang H; Lugar J; Liao Z; Henschel C; Petersen E; Vandevert C; Shoemaker M; Wehner N; Mutter L; Shopp G; Krimm M; Chen L; Wipke B; Dofiles L; Gallager I; Sauer JM; Messersmith EK; Pleiss MA; Bard F; Yednock TA
Bioorg Med Chem Lett; 2013 Aug; 23(15):4370-3. PubMed ID: 23777782
[TBL] [Abstract][Full Text] [Related]
37. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
[TBL] [Abstract][Full Text] [Related]
38. Estimating mass balance for inhaled drugs in humans: an example with a VLA-4 antagonist, IVL745.
Rohatagi S; Shah B; Zhang J; Zeng Z; Kirkesseli S; Jensen BK
J Clin Pharmacol; 2004 Apr; 44(4):348-58. PubMed ID: 15051741
[TBL] [Abstract][Full Text] [Related]
39. Pyridone derivatives as potent and selective VLA-4 integrin antagonists.
Witherington J; Bordas V; Gaiba A; Green PM; Naylor A; Parr N; Smith DG; Takle AK; Ward RW
Bioorg Med Chem Lett; 2006 Apr; 16(8):2256-9. PubMed ID: 16455247
[TBL] [Abstract][Full Text] [Related]
40. Efficient synthesis of 3-aminocyclobut-2-en-1-ones: squaramide surrogates as potent VLA-4 antagonists.
Brand S; de Candole BC; Brown JA
Org Lett; 2003 Jun; 5(13):2343-6. PubMed ID: 12816444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
